GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Cash, Cash Equivalents, Marketable Securities

Arch Biopartners (TSXV:ARCH) Cash, Cash Equivalents, Marketable Securities : C$0.30 Mil (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners Cash, Cash Equivalents, Marketable Securities?

Arch Biopartners's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 (C$1.40 Mil) to Sep. 2023 (C$0.83 Mil) but then stayed the same from Sep. 2023 (C$0.83 Mil) to Dec. 2023 (C$0.30 Mil).

Arch Biopartners's annual cash, cash equivalents, marketable securities increased from Sep. 2021 (C$0.45 Mil) to Sep. 2022 (C$0.51 Mil) and increased from Sep. 2022 (C$0.51 Mil) to Sep. 2023 (C$0.83 Mil).


Arch Biopartners Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Arch Biopartners's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Cash, Cash Equivalents, Marketable Securities Chart

Arch Biopartners Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.40 0.65 0.45 0.51 0.83

Arch Biopartners Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.71 1.40 0.83 0.30

Arch Biopartners Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Arch Biopartners  (TSXV:ARCH) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Arch Biopartners Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Arch Biopartners (TSXV:ARCH) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
545 King Street West, Toronto, ON, CAN, M5V 1M1
Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.